(LYRA) – Globe Newswire
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Participate in Upcoming Investor Conferences
-
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
-
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
-
Lyra Therapeutics to Participate in Upcoming Investor Conferences
-
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Lyra Therapeutics to Present at Jefferies Healthcare Conference
-
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
-
Lyra Therapeutics Announces $50.0 Million Private Placement
-
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
-
Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
-
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Lyra Therapeutics to Present at Upcoming Investor Conferences
-
Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
-
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
-
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
-
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
-
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
-
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
-
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
-
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
-
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
-
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
-
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
-
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
-
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
-
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
-
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
-
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
-
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
-
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
-
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Back to LYRA Stock Lookup
